Publications by authors named "Alexander Constantinides"

Claim this Profile
T
Treatment of colorectal peritoneal metastases with oxaliplatin induces biomarkers predicting response to immune checkpoint blockade.
Alexander Constantinides, Nico Lansu, Peter Mosen, Paulien Rauwerdink, Esther Strating

Transl Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II).
Paulien Rauwerdink, Vincent C J van de Vlasakker, Emma C E Wassenaar, Koen P Rovers, Maartje Los, Alexander Constantinides

Eur J Surg Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploiting a subtype-specific mitochondrial vulnerability for successful treatment of colorectal peritoneal metastases.
Sanne Bootsma, Mark P G Dings, Job Kesselaar, Roxan F C P A Helderman, Kyah van Megesen, Alexander Constantinides

Cell Rep Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: A proof-of-concept study.
Niek A Peters, Alexander Constantinides, Inge Ubink, Joyce van Kuik, Haiko J Bloemendal

Front Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity.
Jamila Laoukili, Alexander Constantinides, Emma C E Wassenaar, Sjoerd G Elias, Danielle A E Raats

Br J Cancer· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid.
Iris Van't Erve, Koen P Rovers, Alexander Constantinides, Karen Bolhuis, Emma Ce Wassenaar

J Pathol Clin Res· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II).
Robin J Lurvink, Paulien Rauwerdink, Koen P Rovers, Emma C E Wassenaar, Maarten J Deenen, Alexander Constantinides

BMJ Open· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial.
Nadine Leonie de Boer, Alexandra R M Brandt-Kerkhof, Eva V E Madsen, Marjolein Diepeveen, Esther van Meerten, Alexander Constantinides

BMJ Open· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a Dutch, multicentre, open-label, single-arm, phase II study (CRC-PIPAC).
Koen P Rovers, Robin J Lurvink, Emma Ce Wassenaar, Thomas Jm Kootstra, Harm J Scholten, Alexander Constantinides

BMJ Open· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma Lp-PLA(2) mass and apoB-lipoproteins that carry Lp-PLA(2) decrease after sodium.
Alexander Constantinides, Michiel N Kerstens, Bert D Dikkeschei, L Joost van Pelt, Constantinos C Tellis

Eur J Clin Invest· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
Alexander Constantinides, Rindert de Vries, Jeroen J J van Leeuwen, Thomas Gautier, L Joost van Pelt

Eur J Intern Med· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.
Alexander Constantinides, Paul J W H Kappelle, Gilles Lambert, Robin P F Dullaart

Arch Med Res· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carotid intima media thickness is associated with plasma lipoprotein-associated phospholipase A2 mass in nondiabetic subjects but not in patients with type 2 diabetes.
Alexander Constantinides, L Joost van Pelt, Jeroen J J van Leeuwen, Rindert de Vries, René A Tio

Eur J Clin Invest· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma cholesteryl ester transfer, but not cholesterol esterification, is related to lipoprotein-associated phospholipase A2: possible contribution to an atherogenic lipoprotein profile.
Robin P F Dullaart, Alexander Constantinides, Frank G Perton, Jeroen J J van Leeuwen, Joost L van Pelt

J Clin Endocrinol Metab· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis